Experimental intraocular penetration of dacarbazine.
Radioactive carbon (14C)-labeled dacarbazine was used to trace penetration of the drug to the eye after intravenous and subtenon-retrobulbar injection on experimental animals. After subtenonretrobulbar injection of 1 or 2.5 mg of commercial dacarbazine twice daily for two weeks, there were no clinical changes. However, doses of 5 to 7.5 mg per injection produced destructive chorioretinitis, and a proliferative type of retinopathy was confirmed histopathologically.